Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Elite Pharmaceuticals ( (ELTP) ).
Elite Pharmaceuticals, Inc., a specialty generics developer based in Northvale, N.J., focuses on immediate-release and controlled-release solid oral dose products, which it markets under its Elite Laboratories label and through licensed third-party distributors. The company operates a cGMP- and DEA-registered facility dedicated to research, development, and manufacturing of these niche generic pharmaceutical products.
On February 11, 2026, Elite announced it would release financial results for the third quarter of its 2026 fiscal year, ended December 31, 2025, on February 17, 2026. Management plans to host a live conference call on February 18, 2026, at 11:30 a.m. EST to discuss financial and operating performance and to provide a corporate update, signaling ongoing engagement with investors and a focus on transparency around business progress.
Stockholders were invited to submit general and financial questions ahead of the February 18 call, indicating an effort to structure the discussion around investor priorities. An audio replay of the event will be made available online, extending access to stakeholders who cannot participate live and supporting broader dissemination of the company’s financial and strategic messaging.
The most recent analyst rating on (ELTP) stock is a Buy with a $0.42 price target. To see the full list of analyst forecasts on Elite Pharmaceuticals stock, see the ELTP Stock Forecast page.
Spark’s Take on ELTP Stock
According to Spark, TipRanks’ AI Analyst, ELTP is a Neutral.
The score is driven primarily by strong current financial performance and a very favorable earnings update highlighting rapid growth and improving profitability/cash generation. These strengths are tempered by weak technical trends and a high P/E valuation, which increase sensitivity to any margin pressure or growth normalization.
To see Spark’s full report on ELTP stock, click here.
More about Elite Pharmaceuticals
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic drug products. Its portfolio focuses on immediate-release and controlled-release solid oral dose formulations, marketed under the Elite Laboratories label and via licensed third-party marketing and distribution partners, with operations centered at a cGMP and DEA-registered facility in Northvale, N.J.
The company leverages its regulated manufacturing base to serve the generic pharmaceuticals market, emphasizing differentiated dosage forms and contract-based commercialization. Its positioning in niche generics targets specific therapeutic needs and partnerships with other pharmaceutical organizations for broader market reach and scale efficiencies.
Average Trading Volume: 745,289
Technical Sentiment Signal: Sell
Current Market Cap: $484.6M
See more insights into ELTP stock on TipRanks’ Stock Analysis page.